US6700024010 - Common Stock
NOVAVAX INC
NASDAQ:NVAX (4/24/2024, 7:20:03 PM)
Premarket: 4.15 0 (0%)4.15
-0.04 (-0.95%)
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 1,992 full-time employees. The firm has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. The company is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.
NOVAVAX INC
700 Quince Orchard Road
Gaithersburg MARYLAND 20878
P: 12402682000
CEO: Stanley C. Erck
Employees: 1992
Website: https://www.novavax.com/
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.
Catalysts lie ahead for both of these companies.
Who wins this face-to-face between two beaten-down biotechs?
Is there still too much risk surrounding this business?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
Here you can normally see the latest stock twits on NVAX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: